Rhumbline Advisers Xtl Biopharmaceuticals LTD Transaction History
Rhumbline Advisers
- $105 Billion
- Q2 2024
A detailed history of Rhumbline Advisers transactions in Xtl Biopharmaceuticals LTD stock. As of the latest transaction made, Rhumbline Advisers holds 5,584 shares of XTLB stock, worth $13,624. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,584Holding current value
$13,624% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding XTLB
# of Institutions
6Shares Held
452KCall Options Held
0Put Options Held
0-
Noked Capital LTD Tel Aviv, L3199KShares$485,2860.02% of portfolio
-
Noked Israel LTD Ramat Hasharon, L3199KShares$485,2860.13% of portfolio
-
Morgan Stanley New York, NY33.2KShares$80,8880.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il15.4KShares$37,6610.0% of portfolio
-
Concourse Financial Group Securities, Inc. Birmingham, AL0Shares$00.0% of portfolio
About XTL BIOPHARMACEUTICALS LTD
- Ticker XTLB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 5,449,060
- Market Cap $13.3M
- Description
- XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Ye...